Literature DB >> 2559537

Cross-neutralizing and subclass characteristics of antibody from horses with equine infectious anemia virus.

K I O'Rourke1, L E Perryman, T C McGuire.   

Abstract

Antibody responses in horses with equine infectious anemia virus (EIAV) were examined to determine their cross-neutralizing capacity. Antibodies induced by infection with any of six biologically cloned variants of EIAV cross-neutralized multiple variants from the group. Anti-EIAV antibody was found in both the IgG and IgG(T) subclasses in plasmas with virus-neutralizing activity and the majority of antiviral antibody was of the IgG(T) subclass. Depletion of IgG(T) did not increase the neutralization indexes of either neutralizing or non-neutralizing plasma samples.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2559537     DOI： 10.1016/0165-2427(89)90108-6

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN： 0165-2427            Impact factor:   2.046


  10 in total

1.  Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.

Authors:  S A Hammond; F Li; B M McKeon; S J Cook; C J Issel; R C Montelaro
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Molecular detection, epidemiology, and genetic characterization of novel European field isolates of equine infectious anemia virus.

Authors:  Katia Cappelli; Stefano Capomaccio; Frank R Cook; Michela Felicetti; Maria Luisa Marenzoni; Giacomo Coppola; Andrea Verini-Supplizi; Mauro Coletti; Fabrizio Passamonti
Journal:  J Clin Microbiol       Date:  2010-11-17       Impact factor: 5.948

3.  Protective effects of broadly neutralizing immunoglobulin against homologous and heterologous equine infectious anemia virus infection in horses with severe combined immunodeficiency.

Authors:  Sandra D Taylor; Steven R Leib; Wuwei Wu; Robert Nelson; Susan Carpenter; Robert H Mealey
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

4.  Selection of a rare neutralization-resistant variant following passive transfer of convalescent immune plasma in equine infectious anemia virus-challenged SCID horses.

Authors:  Sandra D Taylor; Steven R Leib; Susan Carpenter; Robert H Mealey
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

5.  Evolution of the equine infectious anemia virus long terminal repeat during the alteration of cell tropism.

Authors:  Wendy Maury; Robert J Thompson; Quentin Jones; Sarahann Bradley; Tara Denke; Prasith Baccam; Matthew Smazik; J Lindsay Oaks
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Early detection of dominant Env-specific and subdominant Gag-specific CD8+ lymphocytes in equine infectious anemia virus-infected horses using major histocompatibility complex class I/peptide tetrameric complexes.

Authors:  Robert H Mealey; Amin Sharif; Shirley A Ellis; Matt H Littke; Steven R Leib; Travis C McGuire
Journal:  Virology       Date:  2005-08-15       Impact factor: 3.616

7.  Equine monoclonal antibodies recognize common epitopes on variants of equine infectious anaemia virus.

Authors:  L E Perryman; K I O'Rourke; P H Mason; T C McGuire
Journal:  Immunology       Date:  1990-12       Impact factor: 7.397

8.  Failure of low-dose recombinant human IL-2 to support the survival of virus-specific CTL clones infused into severe combined immunodeficient foals: lack of correlation between in vitro activity and in vivo efficacy.

Authors:  Robert H Mealey; Matt H Littke; Steven R Leib; William C Davis; Travis C McGuire
Journal:  Vet Immunol Immunopathol       Date:  2007-07-25       Impact factor: 2.046

9.  Adaptive immunity is the primary force driving selection of equine infectious anemia virus envelope SU variants during acute infection.

Authors:  Robert H Mealey; Steven R Leib; Sarah L Pownder; Travis C McGuire
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 10.  The immunopathogenesis of equine infectious anemia virus.

Authors:  D C Sellon; F J Fuller; T C McGuire
Journal:  Virus Res       Date:  1994-05       Impact factor: 3.303
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.